Panbela Therapeutics, Inc. (PBLA)
USD 0.26
(-3.7%)
USD 0.26
(-3.7%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -51.29 Million USD | -50.45% |
| 2022 | -34.09 Million USD | -240.59% |
| 2021 | -10.01 Million USD | -73.97% |
| 2020 | -5.75 Million USD | -33.13% |
| 2019 | -4.32 Million USD | -11.08% |
| 2018 | -3.89 Million USD | 35.32% |
| 2017 | -6.01 Million USD | -16.41% |
| 2016 | -5.16 Million USD | 5.07% |
| 2015 | -5.44 Million USD | -7120.35% |
| 2014 | -75.39 Thousand USD | 61.2% |
| 2013 | -194.32 Thousand USD | -168.71% |
| 2012 | 282.8 Thousand USD | 370.62% |
| 2011 | -104.5 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -6.72 Million USD | 4.51% |
| 2024 Q2 | -8.1 Million USD | -20.47% |
| 2023 Q3 | -15.69 Million USD | -167.01% |
| 2023 FY | -51.29 Million USD | -50.45% |
| 2023 Q1 | -4.86 Million USD | 5.15% |
| 2023 Q2 | -5.87 Million USD | -20.93% |
| 2023 Q4 | -7.04 Million USD | 55.11% |
| 2022 Q2 | -21.28 Million USD | -431.62% |
| 2022 Q1 | -4 Million USD | -20.57% |
| 2022 FY | -34.09 Million USD | -240.59% |
| 2022 Q4 | -5.12 Million USD | -41.43% |
| 2022 Q3 | -3.62 Million USD | 82.98% |
| 2021 FY | -10.01 Million USD | -73.97% |
| 2021 Q2 | -2.22 Million USD | 0.98% |
| 2021 Q4 | -3.32 Million USD | -50.27% |
| 2021 Q3 | -2.21 Million USD | 0.72% |
| 2021 Q1 | -2.24 Million USD | -40.41% |
| 2020 Q2 | -1.1 Million USD | -3.56% |
| 2020 Q4 | -1.6 Million USD | 19.79% |
| 2020 Q3 | -1.99 Million USD | -80.8% |
| 2020 Q1 | -1.06 Million USD | 15.06% |
| 2020 FY | -5.75 Million USD | -33.13% |
| 2019 Q4 | -1.25 Million USD | 6.48% |
| 2019 Q3 | -1.34 Million USD | -23.35% |
| 2019 Q2 | -1.08 Million USD | -66.62% |
| 2019 Q1 | -653 Thousand USD | -2.51% |
| 2019 FY | -4.32 Million USD | -11.08% |
| 2018 Q1 | -1.23 Million USD | 31.56% |
| 2018 FY | -3.89 Million USD | 35.32% |
| 2018 Q4 | -637 Thousand USD | 30.53% |
| 2018 Q3 | -917 Thousand USD | 15.41% |
| 2018 Q2 | -1.08 Million USD | 12.44% |
| 2017 Q4 | -1.8 Million USD | -73.11% |
| 2017 Q1 | -1.99 Million USD | 5.63% |
| 2017 Q2 | -1.16 Million USD | 41.73% |
| 2017 Q3 | -1.04 Million USD | 10.07% |
| 2017 FY | -6.01 Million USD | -16.41% |
| 2016 Q4 | -2.11 Million USD | -86.17% |
| 2016 FY | -5.16 Million USD | 5.07% |
| 2016 Q2 | -949 Thousand USD | 2.67% |
| 2016 Q3 | -1.13 Million USD | -19.6% |
| 2016 Q1 | -975 Thousand USD | 20.73% |
| 2015 Q2 | -81.59 Thousand USD | -4.88% |
| 2015 FY | -5.44 Million USD | -7120.35% |
| 2015 Q4 | -1.23 Million USD | -59.74% |
| 2015 Q3 | -770 Thousand USD | -843.69% |
| 2015 Q1 | -77.79 Thousand USD | -147.03% |
| 2014 Q3 | -87.37 Thousand USD | -74.97% |
| 2014 FY | -75.39 Thousand USD | 61.2% |
| 2014 Q2 | -49.93 Thousand USD | 51.75% |
| 2014 Q1 | -103.49 Thousand USD | -601.8% |
| 2014 Q4 | 165.41 Thousand USD | 289.31% |
| 2013 Q3 | -54.26 Thousand USD | -24.84% |
| 2013 Q2 | -43.46 Thousand USD | 42.69% |
| 2013 FY | -194.32 Thousand USD | -168.71% |
| 2013 Q4 | -14.74 Thousand USD | 72.82% |
| 2013 Q1 | -75.84 Thousand USD | -160.71% |
| 2012 FY | 282.8 Thousand USD | 370.62% |
| 2012 Q3 | 82.72 Thousand USD | -18.28% |
| 2012 Q4 | 124.92 Thousand USD | 51.0% |
| 2012 Q1 | -26.07 Thousand USD | 0.0% |
| 2012 Q2 | 101.23 Thousand USD | 488.19% |
| 2011 FY | -104.5 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| America Great Health | -492.64 Thousand USD | -10311.981% |
| Ampio Pharmaceuticals, Inc. | -9.51 Million USD | -438.916% |
| Aridis Pharmaceuticals, Inc. | -29.99 Million USD | -71.02% |
| Biora Therapeutics, Inc. | -67.14 Million USD | 23.605% |
| Bio-Path Holdings, Inc. | -15.84 Million USD | -223.764% |
| Better Therapeutics, Inc. | -38.26 Million USD | -34.06% |
| Calithera Biosciences, Inc. | -42.07 Million USD | -21.914% |
| Comera Life Sciences Holdings, Inc. | -11.97 Million USD | -328.521% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.84 Million USD | -51.56% |
| Eloxx Pharmaceuticals, Inc. | -34.41 Million USD | -49.028% |
| Evelo Biosciences, Inc. | -108.46 Million USD | 52.71% |
| Evolutionary Genomics, Inc. | -2.01 Million USD | -2446.49% |
| Finch Therapeutics Group, Inc. | -34 Million USD | -50.856% |
| Galera Therapeutics, Inc. | -46.95 Million USD | -9.25% |
| Innovation1 Biotech Inc. | -1.36 Million USD | -3651.245% |
| Kiromic BioPharma, Inc. | -19.93 Million USD | -157.251% |
| Molecular Templates, Inc. | -10.46 Million USD | -390.101% |
| Navidea Biopharmaceuticals, Inc. | -14.05 Million USD | -265.059% |
| NexImmune, Inc. | -29.19 Million USD | -75.71% |
| Orgenesis Inc. | -53.63 Million USD | 4.366% |
| Point of Care Nano-Technology, Inc. | -78.01 Thousand USD | -65647.209% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | -217.703% |
| Scopus BioPharma Inc. | -11.71 Million USD | -337.854% |
| Sorrento Therapeutics, Inc. | -504.31 Million USD | 89.829% |
| Statera Biopharma, Inc. | -98.34 Million USD | 47.842% |
| TRACON Pharmaceuticals, Inc. | -6.89 Million USD | -643.607% |
| Trevena, Inc. | -35.28 Million USD | -45.358% |
| Vaxxinity, Inc. | -58.28 Million USD | 11.995% |
| Vaccinex, Inc. | -22.88 Million USD | -124.138% |
| Vicapsys Life Sciences, Inc. | -1.04 Million USD | -4799.243% |
| Viracta Therapeutics, Inc. | -50.69 Million USD | -1.186% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | -606.236% |